FDA approves first-in-class treatment for rare adrenal tumors
The US FDA has approved Progenics Pharmaceuticals’ Adzera®, a first-in-class treatment for two rare adrenal tumors: pheochromocytoma and paraganglioma.
Please sign in or register for FREE
Sign in to RxNet
Register to RxNet
RxNet is a communal space where industry and academic professionals can come together to discuss the latest research and developments, share thoughts and opinions, and build valuable international relationships.